Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 9.77% | |
| Up 3 Days in a Row | Strength | 9.77% | |
| NR7 | Range Contraction | 14.70% | |
| NR7-2 | Range Contraction | 14.70% | |
| Earnings Movers | Other | 14.70% | |
| Gapped Up | Strength | 14.70% | |
| Crossed Above 20 DMA | Bullish | 16.19% | |
| NR7 | Range Contraction | 16.19% | |
| Earnings Movers | Other | 16.19% | |
| Inside Day | Range Contraction | 16.19% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 1 hour ago |
| Rose Above 50 DMA | about 1 hour ago |
| Up 1 ATR | about 3 hours ago |
| Up 5% | about 3 hours ago |
| Upper Bollinger Band Resistance | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Solid Tumor Cancers Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.62 |
| 52 Week Low | 1.3 |
| Average Volume | 358,769 |
| 200-Day Moving Average | 1.99 |
| 50-Day Moving Average | 1.76 |
| 20-Day Moving Average | 1.51 |
| 10-Day Moving Average | 1.58 |
| Average True Range | 0.10 |
| RSI (14) | 51.46 |
| ADX | 21.09 |
| +DI | 22.45 |
| -DI | 19.86 |
| Chandelier Exit (Long, 3 ATRs) | 1.46 |
| Chandelier Exit (Short, 3 ATRs) | 1.69 |
| Upper Bollinger Bands | 1.69 |
| Lower Bollinger Band | 1.34 |
| Percent B (%b) | 0.83 |
| BandWidth | 23.38 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0265 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.77 | ||||
| Resistance 3 (R3) | 1.75 | 1.70 | 1.74 | ||
| Resistance 2 (R2) | 1.70 | 1.66 | 1.70 | 1.73 | |
| Resistance 1 (R1) | 1.66 | 1.64 | 1.68 | 1.68 | 1.73 |
| Pivot Point | 1.61 | 1.61 | 1.62 | 1.61 | 1.61 |
| Support 1 (S1) | 1.57 | 1.57 | 1.59 | 1.59 | 1.53 |
| Support 2 (S2) | 1.52 | 1.55 | 1.52 | 1.53 | |
| Support 3 (S3) | 1.48 | 1.52 | 1.52 | ||
| Support 4 (S4) | 1.50 |
